Ligand(US:LGND) Investors·2026-03-10 21:13Core Insights - Ligand Pharmaceuticals has experienced a significant stock breakout, surpassing multiple buy points and achieving a closing price of $212.29, reflecting a 2% increase [1] - The company operates as an investment entity in the biotech sector, managing over 100 partnered commercial and development-stage programs, which generate royalties from successful drug sales [1] - Following a strong fourth-quarter report, Ligand's royalty revenue is projected to increase by 50% at the midpoint of its guidance [1] Company Performance - Ligand's stock has achieved a strong IBD Composite Rating of 96, ranking it in the top 4% of all stocks based on fundamental and technical measures [1] - The Relative Strength Rating stands at 92, indicating that Ligand's performance over the past 12 months is in the leading 8% of all stocks [1] - The stock's relative strength line is at a record high, showcasing its outperformance compared to the S&P 500 [1] Key Partnerships and Products - Major products include Filspari, partnered with Travere Therapeutics, which generated $9.3 million in royalties, and Ohtuvayre, partnered with Merck, which achieved $196 million in fourth-quarter sales, a 45% sequential increase [1] - Filspari is aimed at treating primary IgA nephropathy and has potential for additional sales in treating focal segmental glomerulosclerosis, with peak sales estimated at $1 billion [1] - Ohtuvayre is approaching blockbuster status, with total sales for 2026 projected to reach $1 billion [1] Oncology Pipeline - Ligand has a diverse oncology pipeline, including partnerships for drugs like Qarziba for neuroblastoma and a drug in collaboration with Leona Bio for breast cancer and osteoporosis [1] - The company is also working with Agenus on a colorectal cancer drug, with royalties ranging from 2.6% to 10% depending on the product [1] - Oppenheimer analyst raised the price target for Ligand stock to $277, reflecting confidence in the company's growth potential [1]